Quest PharmaTech Inc.

QPT

CA74836M1068

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 19:35:42 31/05/2024 BST			5-day change	1st Jan Change
0.02 ^CAD	-33.33%		-33.33%	-63.64%

05-30	Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	CI
01-30	Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	MT

Quest PharmaTech, Inc. Announces Board of Directors Elections

November 10, 2014 at 06:20 pm

Quest PharmaTech, Inc. elected Lorne Meikle and Bin Huang to Board of Directors at its AGM held on November 10, 2014.

Latest news about Quest PharmaTech Inc.

Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	05-30	CI
Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	01-30	MT
Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	01-30	MT
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis	01-24	MT
Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study	01-23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	12-13	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	21/09/23	CI
Quest PharmaTech Provided Product Development Update	10/07/23	MT
Quest PharmaTech Inc. Provides Product Development Update	10/07/23	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	29/06/23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	31/05/23	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	30/05/23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	18/12/22	CI
Quest PharmaTech Details Bioceltran Interest Sale, Return of Photodynamic Therapy Technology License	28/09/22	MT
Sang Ho Jang acquired unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. for CAD 0.3 million.	27/09/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	26/09/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2022	27/06/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2022	26/05/22	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	25/05/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	23/12/21	CI
Quest Pharmatech Inc. Reports Earnings Results for the Second Quarter Ended July 31, 2021	23/09/21	CI
Quest PharmaTech Inc. Approves Appointment of J. Mark Lievonen and Jeffrey Shon as Board of Directors	07/07/21	CI
Quest Pharmatech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2021	22/06/21	CI
Quest Pharmatech Inc. Reports Earnings Results for the Full Year Ended January 31, 2021	31/05/21	CI
Quest PharmaTech Inc.(TSXV:QPT) dropped from S&P/TSX Venture Composite Index	19/04/21	CI

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.âs technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

Sector

Biotechnology & Medical Research

Calendar

25/06/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUEST PHARMATECH INC.	-63.64%	3.71M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B